Physician profile
Jonathan D Pewitt
NPI 1912198979
$2,577.66
in general payments reported to CMS, 2019-2025
18 companies · $820 in 2025
The $820 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.22 · 2020: $35.99 · 2021: $34.10 · 2022: $409 · 2023: $631 · 2024: $556 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,917 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,917.40 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $835.49 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $403.47 | 2022-2025 | Sotyktu |
| Ucb, INC. | $172.69 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $166.33 | 2022-2025 | Tremfya |
| Dermavant Sciences, INC. | $146.12 | 2023-2024 | Vtama |
| Genzyme Corporation | $121.09 | 2022-2024 | |
| Incyte Corporation | $116.82 | 2023 | Opzelura |
| Novartis Pharmaceuticals Corporation | $104.94 | 2023-2025 | |
| Amgen INC. | $95.53 | 2020-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $92.22 | 2019-2023 | Winlevi, Absorica Ld |
| Leo Pharma INC. | $87.55 | 2022-2023 | Adbry |
| Lilly USA, LLC | $76.22 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $73.10 | 2020-2025 | Nemluvio, Aklief |
| Organon LLC | $23.29 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.91 | 2023 | Spevigo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19.10 | 2021 | |
| Celgene Corporation | $17.06 | 2019 | |
| Mayne Pharma Commercial LLC | $4.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Pewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.